Precision Medicine News and Updates | Precision Medicine Online
Precision Medicine Online provides the latest news for healthcare leaders and scientists interested in precision medicine and individualized approaches to treatment and prevention.
Breaking News - Precision Medicine Online
2024年11月20日 · The approval is based on the objective response rate in a Phase IIb trial of previously treated, unresectable or metastatic biliary tract cancer patients.
Precision Oncology News - Precision Medicine Online
2024年11月18日 · The latest news on companion diagnostics and personalized cancer therapy from Precision Medicine Online.
Breaking News - Precision Medicine Online
2024年11月11日 · Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.
About Us - Precision Medicine Online
Precision Medicine Online is published by GenomeWeb, an independent online news organization based in New York. Since 1997, GenomeWeb has served the global community of scientists, …
Disease Research & Diagnostics News | Precision Medicine Online
News and analysis on disease research and diagnostics from Precision Medicine Online.
Genomics Technology, Tools & Methods - Precision Medicine Online
2024年10月29日 · The latest news on life science tools and technology in genetics, genomics, and molecular diagnostics from Precision Medicine Online.
Precision Oncology Precision Oncology News - Precision Medicine …
2024年10月7日 · The test is approved for patients with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.
Genomics Research & Discovery | Precision Medicine Online
2024年10月8日 · The latest research news in genetics and genomics from Precision Medicine Online.
Frequently Asked Questions | Precision Medicine Online
Precision Medicine Online, launched in 2023, is an expansion of Precision Oncology News, which was created in 2019 to cover the application of genomic sequencing and other biomarker …